
    
      1. To compare FEC*6 with FEC*3 followed by DOC*3 with regard to:

             -  the primary endpoint of the study: Disease-Free Survival (DFS)

             -  the secondary endpoints: Overall Survival (OS), compliance, and toxicity of
                chemotherapy in each patient group

        2. To compare patients with low risk according to clinico-pathological versus those
           according to biological risk criteria with regard to:

             -  the proportion of low risk versus high risk patients

             -  DFS

             -  OS (secondary endpoint)
    
  